Atopic dermatitis (AD) is a common disease of childhood, and infantile AD may manifest from birth to 2 years. Guidelines for the management of infantile AD are lacking, and our aim is to provide a comprehensive review of best practices and possible interven-tions. We will focus on topical therapy, since the use of systemic immunomodulating agents in infantile AD is rarely advised. Topical agents include emollients, topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), and phosphodiesterase 4 (PDE-4) inhibitors. We will also provide a brief overview of promising emerging therapies currently under investi-gation in the pediatric population.
CITATION STYLE
Davari, D. R., Nieman, E. L., McShane, D. B., & Morrell, D. S. (2020). Current perspectives on the management of infantile atopic dermatitis. Journal of Asthma and Allergy. Dove Medical Press Ltd. https://doi.org/10.2147/JAA.S246175
Mendeley helps you to discover research relevant for your work.